Benzinga Bulls And Bears: Tesla, Microsoft, Apple, Novavax And Why Dogecoin May Be Poised For 50% Surge
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising
The U.S. government invested at least $31.9 billion to develop, produce, and purchase mRNA COVID-19 vaccines, including sizeable…
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Exelixis Inc (NASDAQ:EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS). CONTACT-03 is…
$300B California Teachers Pension Fund Joins Politan Capital In Legal Action Against Masimo CEO’s Employment Agreement
The California State Teachers’ Retirement System (CalSTRS) has joined Politan Capital Management to stop Masimo Corp’s (NASDAQ:MASI) CEO from receiving…
Walgreens Boots Alliance Nixes Dispersing Abortion Medication In 20 Republican States
Walgreens Boots Alliance Inc (NASDAQ: WBA) reportedly confirmed that it would not dispense abortion pills in several states where they remain legal.
The European Commission Has Approved Bristol Myers Squibb’s Reblozyl (Luspatercept) For Anemia Associated With Non-transfusion-dependent Beta-thalassemia
The EC approval of Reblozyl was based on results from the Phase 2 BEYOND study, evaluating the efficacy and safety of Reblozyl versus placebo in 145 adults with NTD beta thalassemia. Patients were
Biden Admin’s Upcoming Cybersecurity Strategy Can Potentially Put Businesses, Software Provides On Collision Course
The Biden administration is poised to release a new national cybersecurity strategy that aims to make software companies liable for security hacks rather than the companies facing the hack.
Silvergate Capital Plagued By ‘Regulatory And Liquidity Challenges,’ JPMorgan Analyst Says
Shares of cryptocurrency-focused Silvergate Capital Corp (NYSE: SI) fell off of a cliff Thursday, plummeting 45% on its warning of a delay in its annual report and concerns over its
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK’s Candidate Soon After Pfizer’s
The FDA’s Vaccines and Related Biological Products Advisory Committee voted that GSK plc’s (NYSE:GSK) available data support the safety and effectiveness of…
AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says
Guggenheim initiated coverage on AbbVie Inc (NYSE:ABBV) with a Buy and a price target of $172 on diversified growth. Investors have “naturally” been…